Look at what all the partnerships have done for ARRY - absolutely nothing but give ARRY cash; in fact, I think all the partnerships have hurt ARRYs stock in terms of essentially wiping out any takeover premium.
I am glad Celldex is deciding to start a pivotal trial without a partner. They will be able to retain ownership of the asset, and also not get held back by some pharma that will likely move at stall speed, going through blue-ribbon multi-level executive meetings for a year deciding on how to run a trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.